XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Among these is the receptor occupancy assay, which is a powerful method used to understand how a therapeutic drug binds to (or occupies ) its receptors on the surface of certain cells.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all. .”

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

pharmaphorum

AUGUST 5, 2021

It will supply hard-to-make radiochemicals to drug discovery biotechs and academic innovators – increasing the UK’s potential to discover new and better therapies for patients, faster. In recent years MDC and the WMIC have jointly delivered a pipeline of commercial and grant-funded PET imaging projects for UK drug discovery innovators.

Medicine 52

Medicine In-Vivo Packaging Packaging 52

The Pharma Data

NOVEMBER 24, 2020

Fidelta, located in R&D facilities in Croatia, currently has 181 employees, including more than 150 scientists. The acquisition, which is expected to close in January 2021, will expand Selvita’s integrated drug discovery services and will check off one of the company’s 2020 to 2023 goals it announced in April.

Drugs 52

Drugs In-Vivo Marketing Development 52

pharmaphorum

APRIL 6, 2021

Shiva Kazerounian , Associate Director & Principal Scientist – In Vivo Pharmacology, Berg Health. Aaron Goldman , Director, Drug Resistance Group, Harvard Medical School. There is a crucial need to progress candidates from bench to bedside. Boris Engels , Associate Director, Novartis.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

pharmaphorum

APRIL 29, 2021

This Hanson Wade event is aimed at experts looking to deliver CNS drug candidates safely and successfully across the blood-brain barrier (BBB). Discover the role of neural extracellular vesicles in non-invasive CNS drug delivery, and how the properties of extracellular vesicles can be enhanced with unique surface modifications.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

FDA Law Blog

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 42 U.S.C. §

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

The Pharma Data

NOVEMBER 10, 2020

This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing. We’re seeing a trend in drug development towards super complex and highly-targeted compounds, which requires researchers to conduct a number of preclinical studies.

Marketing 52

Marketing In-Vivo Scientist Research 52

Delveinsight

FEBRUARY 11, 2021

Researchers from the University of Pennsylvania’s Abramson Cancer Center contemplate they have discovered one key to the lack of response, and it may be targetable with different drug combinations, as per their announcement. Enhancing the response to immuno-oncology in pancreatic cancer. Median overall survival in those patients was 5.8

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

XTalks

NOVEMBER 3, 2023

After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based gene therapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

The Pharma Data

JANUARY 11, 2021

CAMBRIDGE, England–( BUSINESS WIRE )– CN Bio , a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA) 1.

In-Vivo 40

In-Vivo Drugs Clinical Trials Clinical Trials 40

XTalks

SEPTEMBER 20, 2024

Such challenges highlight a significant unmet need and call for further advancements in the field. Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

Delveinsight

FEBRUARY 25, 2021

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs).

DNA 52

DNA In-Vivo Genetics Medicine 52

Roots Analysis

OCTOBER 19, 2023

The overuse of antibiotics has resulted in the emergence of multi-drug-resistant bacteria. Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ).

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

The Pharma Data

JANUARY 27, 2021

Ralf Reilmann, MD, PhD, FAAN, Founding Director of the George-Huntington-Institute and European Principal Investigator of the study, said: “PROOF-HD is currently the only Phase 3 study available to early-HD patients in Europe, opening up an exciting opportunity for the patient community with an orally available drug.

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vivo 40

The Pharma Data

NOVEMBER 10, 2020

While the world is facing a severe shortage of specific antiviral drugs, a new treatment developed by Asclepius Meditec highlights the potential of hydrogen-oxygen therapy in tackling COVID-19. . . SHANGHAI , Nov. SHANGHAI , Nov. It is expected to be certificated CE Mark soon.

Medicine 52

Medicine In-Vivo Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 15, 2020

F4 Pharma — In order to help F4 Pharma advance its COVID-19 asset FX06 and to provide strategic guidance, F4 Pharma has appointed a scientific advisory board consisting of clinicians and scientists. The Advance awards recognize the work of remarkable global Australians making an extraordinary impact worldwide.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52